REVIEW



One-anastomosis gastric bypass (OAGB) versus Roux-en-Y gastric bypass (RYGB) as revisional procedures after failed laparoscopic sleeve gastrectomy (LSG): systematic review and meta-analysis of comparative studies

Antonio Vitiello¹ · Giovanna Berardi¹ · Roberto Peltrini² · Pietro Calabrese² · Vincenzo Pilone²

Received: 2 August 2023 / Accepted: 7 November 2023 / Published online: 18 November 2023 © The Author(s) 2023

Abstract

Introduction The aim of this study was to compare weight loss and gastroesophageal reflux disease (GERD) remission after one-anastomosis gastric bypass (OAGB) versus Roux-en-Y gastric bypass (RYGB) as revisional procedures after laparoscopic sleeve gastrectomy (LSG).

Methods In PubMed, Embase, and Cochrane Library, a search was performed using the terms "Roux-en-Y gastric bypass versus one anastomosis gastric bypass," "revisional surgery," and "sleeve gastrectomy." Only original articles in English language comparing OAGB and RYGB were included. No temporal interval was set. The primary outcome measure was weight loss (%TWL). The secondary endpoints were leak, bleeding, marginal ulcer, and GERD. PRISMA flowchart was used. Differences in continuous and dichotomous outcome variables were expressed as mean difference (MD) and risk difference (RD) with 95% CI, respectively. Heterogeneity was assessed by using l^2 statistic.

Results Six retrospective comparative articles were included in the present meta-analysis. Weight loss analysis showed a MD = 5.70 (95% CI 4.84–6.57) in favor of the OAGB procedure with a statistical significance (p = 0.00001) and no significant statistical heterogeneity ($I^2 = 0.00\%$). There was no significant RD for leak, bleeding, or marginal ulcer after the two revisional procedures. After conversion to OAGB, remission from GERD was 68.6% (81/118), and it was 80.6% (150/186) after conversion to RYGB with a RD = 0.10 (95% CI –0.04, 0.24), no statistical significance (p = 0.19), and high heterogeneity ($I^2 = 96\%$). De novo GERD was 6.3% (16/255) after conversional OAGB, and it was 0.5% (1/180) after conversion to RYGB with a RD = -0.23 (95% CI –0.57, 0.11), no statistical significance (p = 0.16), and high heterogeneity ($I^2 = 92\%$).

Keywords Revisional surgery · One-anastomosis gastric bypass · Roux-en-Y gastric bypass · Sleeve gastrectomy · GERD

Antonio Vitiello antoniovitiello_@hotmail.it

> Giovanna Berardi giovannaberardi88@gmail.com

Roberto Peltrini Roberto.peltrini@gmail.com

Pietro Calabrese picalabres@gmail.com

Vincenzo Pilone Vincenzo.pilone@unina.it

¹ Advanced Biomedical Sciences Department, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy

² Public Health Department, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy

Introduction

Laparoscopic sleeve gastrectomy (LSG) is currently the most performed bariatric procedure worldwide [1]. Despite this popularity, LSG was reported to be associated with weight regain and gastroesophageal reflux disease (GERD) in the long-term with a revision rate up to 36% [2]. Some articles have also described intestinal metaplasia (Barrett's disease) after LSG due to the chronic exposure of the lower esophagus to reflux [3, 4]. Roux-en-Y gastric bypass (RYGB) and one-anastomosis gastric bypass (OAGB) are, respectively, the second and the third most performed interventions, and they have both been suggested as good options for failed LSG [2–5]. Specifically, RYGB is considered an efficient treatment for GERD post-LSG [6], while OAGB may provide better results in terms of further weight loss [7].

The aim of this study was to analyze and compare weight loss and GERD remission after OAGB versus RYGB as revisional procedures after LSG.

Methods

Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines were followed [8].

Literature search

In PubMed, Embase, and Cochrane Library, a search was performed using the terms "Roux-en-Y gastric bypass versus one anastomosis gastric bypass," "revisional surgery," and "sleeve gastrectomy." In addition, the reference lists of all retrieved articles were manually reviewed. According to Problem/ Population, Intervention, Comparison, and Outcome (PICO) framework, study selection criteria were exactly defined. Only original articles in English language comparing OAGB and RYGB were included. No temporal interval was set. The primary outcome measure was weight loss. The secondary endpoints were leak, bleeding, GERD remission, and de novo reflux. The last search was performed in December 2022.

Studies selection

Two independent authors analyzed each article and performed data extraction independently. Duplicate studies were removed. In case of disagreement, further investigation was conducted by an additional author.

Statistical analysis

DataRev software (Cochrane) version 5.4.1 (the Cochrane Collaboration 2011, the Nordic Cochrane Centre, Copenhagen) was used to perform a random-effect meta-analysis with Mantel–Haenszel calculation because of the observational nature of most studies included in this analysis.

Differences in continuous and dichotomous outcome variables were expressed as mean difference and risk difference (RD) with 95% CI, respectively. Heterogeneity was assessed by using I^2 statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than chance. Usually, values of the I^2 statistic <25% are indicative of low heterogeneity, those ranging between 25 and 75% of moderate heterogeneity, and those >75% of high heterogeneity. $I^2 < 40\%$ was considered as non-important heterogeneity. A p < 0.05 was considered statistically significant. Publication bias was assessed through visual inspection of funnel plots.

Quality assessment

The Newcastle–Ottawa Quality Assessment Scale (NOS) [9] was used as an assessment tool to evaluate case–control studies. The scale's range varies from 0 to 9 stars, and studies with a score equal to or higher than 5 were considered to have an adequate methodological quality to be included.

Results

The literature search found 55 articles. After removal of 21 duplicates, other 27 articles were excluded because they were not comparing RYGB and OAGB as revisional procedures. Seven [10–15] papers were considered eligible, but one [16] was excluded due to incomplete report of the outcome measures. PRISMA flow chart for the study selection is shown in Fig. 1. Eventually, 5 retrospective articles and 1 randomized controlled trial were included in our meta-analysis (Table 1). In total, 739 patients were included, of which 373 (50.5%) underwent OAGB and 366 (49.5%) underwent RYGB. The sample size of these studies ranged from 55 to 263 patients. The primary outcome measure was reported both as percentage of total weight loss (%TWL) and percentage of excess weight loss (%EWL) or excess BMI loss percent (%EBMIL) with a follow-up ranging from 12 to 60 months; assessment with NOS showed high-quality methodology for all the considered papers (Table 2).

Weight loss was reported using different parameters, but percentage of total weight loss (%TWL) was used in five studies showing a MD = 5.70 (95% CI 4.84–6.57) in favor of the OAGB procedure with a statistical significance (p < 0.001) and no significant statistical heterogeneity ($l^2 = 0\%$) (Fig. 2).

Overall leak rate after conversion to OAGB was 1% (4/373), and it was 1.6% (6/366) after revision to RYGB.

Meta-analysis showed a RD = -0.00 (95% CI - 0.02-0.02) with no statistical significance (p = 0.83) and no significant statistical heterogeneity ($I^2 = 0.00\%$) (Fig. 3).

Total bleedings after revisional OAGB and RYGB were 1.3% (5/373) and 2.2% (8/366), respectively, with a RD = -0.01 (95% CI -0.03, 0.01) with no statistical significance (p = 0.33) and no significant statistical heterogeneity ($I^2 = 0.00\%$) (Fig. 4).

Total percentage of marginal ulcers after conversion to OAGB was 0.8% (3/373), and it was 1.9% (7/366) after revision to RYGB. Meta-analysis showed a RD = -0.01 (95% CI -0.02, 0.01) with no statistical significance (p = 0.51) and low heterogeneity ($I^2 = 16\%$) (Fig. 5).

Fig. 1 PRISMA flowchart



 Table 1
 Included studies and baseline characteristics

Study (year)	Primary surgery	Revisional surgery	Patient (<i>n</i>)	Age (years)	Male (n)	BMI at conversion (kg/m ²)	Max follow-up time (months)	BMI at follow-up (kg/m ²)
Chiappeta (2019)	LSG	OAGB	34	46.76 ± 11.48	11	45.7 ± 8	12	36.6 ± 6.3
		RYGB	21	46.14 ± 10.8	2	36.6 ± 6.9	12	33.5 ± 5.6
Rayman (2021)	LSG	OAGB	144	42.4 ± 10.5	37	41.6 ± 5.7	25.5	31.8 ± 5.3
		RYGB	119	44.3 ± 11.8	35	39.6 ± 5.0	35	33.3 ± 5.0
Felsenreich (2022)	LSG	OAGB	13	-	-	45.0 ± 7.3	15	31.4 ± 8.1
		RYGB	45	-	-	38.6 ± 8.6	15	30.3 ± 8.5
Rheinwalt (2022)	LSG	OAGB	55	42 ± 1.3	33	45.5 ± 1.0	24	35
		RYGB	68	46 ± 1.2		$39.3 \pm 1.0 \text{ kg}$	24	31
Wilczyński (2022)	LSG	OAGB	47	45.02 ± 10.71	13	40.44 ± 5.8	60	-
		RYGB	33	41.24 ± 8.906	6	38.70 ± 6.84	60	-
Hany (2022)	LSG	OAGB	80	42.6 ± 7.1	11	45.1 ± 8.3	24	27.4 ± 3.1
		RYGB	80	43.4 ± 7.5	11	44.9 ± 6.6	24	27.8 ± 2.2

GERD was the indication for conversion for 31.6% (118/373) of patients before OAGB and for 50.8% (186/366) before RYGB. Meta-analysis of rate of preconversional GERD showed a RD = -0.24 (95%) CI - 0.41, -0.06) with statistical significance (p = 0.007) and high heterogeneity ($l^2 = 87\%$) (Fig. 6).

After conversion to OAGB remission from GERD was 68.6% (81/118), and it was 80.6% (150/186) after conversion

Study (year)	Revisional surgery	Operative time (min)	Sample (n)	Leaks (n, %)	Bleeding $(n, \%)$	Marginal ulcer $(n, \%)$	EWL%	%TML	T2DM resolution (%)	HTN resolution (%)	GERD on follow-up (%)	NOS
Chiappeta (2019)	OAGB	79 ± 36	34	0 (0%)	0 (0%) (%0) 0	0 (0%)	29 ± 13	15.8 ± 7.8	100%	66.7% 000	11.8%	6
Rayman (2021)	OAGB	98 ± ∠4 -	21 144	0 (0%) 2 (1.4%)	0 (0%) 2(1.4%)	1 (4.8%) 0 (0%)	22 ± 18 58.7	10.5 ± 1.0 32 ± 9	%00% -	%n -	4.8% 17.4%	6
3	RYGB	ı	119	1(1.7%)	3 (2.5%)	0 (0%)	44.2	27 ± 9		ı	7.6%	
Felsenreich	OAGB		13	0 (0%)	0 (0%)	(%0) 0	80.3 ± 23.7	39.5 ± 11.5	ı	ı	28.9%	6
(2022)	RYGB		45	0 (0%)	0 (0%)	0 (0%) (0%)	79.8 ± 34.1	37.7 ± 14.6		ı	53.8%	
Rheinwalt	OAGB	168 ± 7.2	55	2 (3.6%)	0 (0%)	0 (0%)	50	24 ± 2.6	92%	92%	13.34%	8
(2022)	RYGB	201 ± 6.8	68	4 (5.9%)	2 (2.9%)	0 (0%)	40	18 ± 3.0	100%	89%	11.1%	
Wilczyński	OAGB		47	(%0) (0%)	1 (2.12%)	3 (6.4.%)	84.04 ± 18.81	21.81 ± 12.48	97.3%	27.3%	28.6%	8
(2022)	RYGB		33	0 (0%)	1 (3%)	4 (12.1%)	72.95 ± 20.3	18.39 ± 11.85	33.3%	30%	%09	
Hany (2022)	OAGB	85.6 ± 18.6	80	(%0) (0%)	1 (1.25%)	0 (0%) (0%)	* 1	*,	75%	68%	ı	8
	RYGB	104.9 ± 13.7	80	(%0) (0%)	1 (1.25%)	2 (2.5%)	*	*	71%	75%	ı	
officerus N POW	KYGB	104.9 ± 13.7	80	0 (0%)	1 (1.25%)	2 (2.5%)	*	*	%17		% C/.	- %¢1

De novo GERD was 6.3% (16/255) after conversional OAGB, and it was 0.5% (1/180) after conversion to RYGB with a RD = -0.23 (95% CI -0.57, 0.11) with no statistical significance (p=0.16) and high heterogeneity (I^2 =92%) (Fig. 8).

Funnel plots inspection did not show significant bias (Supplement materials 1–6).

Discussion

LSG was initially introduced by Marceau [17] and Gagner [18] proposed as a first step of a staged procedure in patients with BMI > 60 kg/m [2]. Since postoperative outcomes demonstrated low morbidity and satisfactory weight loss, LSG became a stand-alone bariatric intervention [19]. Short-term studies (1–3 years) reported an excess weight loss (%EWL) comparable to the values of the RYGB [20]. Mid-term reports (5–7 years) have shown less successful results, with a certain percentage of weight regain [21, 22]; the SM-BOSS [23] study showed that excess BMI loss peaked at 2 years after SG (74.7%) but decreased by the end of the fifth year to 61.1%.

Recently, long-term studies have demonstrated a worrisome rate of conversion and GERD [24], especially in individuals with BMI > 50 kg/m² [25]. Sporadic cases of vitamin deficiency after LSG have been also published [26].

A recent systematic review showed a rate of de novo GERD of 20% [27] after LSG, while a meta-analysis found that the increase of postoperative GERD was 19%, and de novo reflux occurred in 23% [28] of patients.

Despite several meta-analyses have investigated the role of OAGB and RYGB as revisional procedures after failed restrictive surgery [6, 7, 29], there is a lack of comparative studies on the role of this interventions specifically after failed LSG. Chiappetta et al. [10] first reported their single-center analysis of 55 patients showing that OAGB after failed SG was a quicker procedure with less perioperative complications. On the contrary, Rayman [12] reported that conversion of LSG to OAGB, compared to RYGB, resulted in increased weight loss with a higher rate of GERD and potential nutritional deficiencies. Instead, Felsenreich et al. [11] have recently concluded that with regard to the fact that OAGB has a low potential to cure patients from GERD symptoms after SG, RYGB is probably the best option for patients post-LSG reflux. Rheinwalt [13] also found comparable results with significantly shorter operation times for OAGB. After a follow-up of 5 years, Wilczyński[14] reported a significant remission of T2DM after OAGB when compared to RYGB after LSG. Hany et al. [15] have

	0	AGB		F	RYGB			Mean Difference			Mean Dif	ference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year		IV, Randor	n, 95% Cl		
Chiappetta 2019	15.8	7.8	34	10.3	7.6	21	4.3%	5.50 [1.32, 9.68]	2019		-	+		
Rayman 2021	32	9	144	27	9	119	15.6%	5.00 [2.81, 7.19]	2021			•		
Felsenreich 2022	39.5	11.5	13	37.7	14.6	45	1.3%	1.80 [-5.77, 9.37]	2022		+	_		
Rheinwalt 2022	24	2.6	55	18	3	68	76.2%	6.00 [5.01, 6.99]	2022					
Wilczyński 2022	21.8	12.5	47	18.4	11.9	33	2.6%	3.40 [-2.01, 8.81]	2022		†	-		
Total (95% CI)			293			286	100.0%	5.70 [4.84, 6.57]				1		
Heterogeneity: Tau² = Test for overall effect:	= 0.00; C Z = 12.9	hi² = 2 }3 (P <	.47, df: 0.0000	= 4 (P = 01)	0.65);	I ² = 0%				-100	-50 0 Favours (RYGB)	5 Favours (OA	0 AGB]	100

Fig. 2 Forest plot for percentage of total weight loss

	OAG	В	RYG	В		Risk Difference		Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
Chiappetta 2019	0	34	0	21	5.6%	0.00 [-0.07, 0.07]	2019	
Rayman 2021	2	144	1	119	47.6%	0.01 [-0.02, 0.03]	2021	•
Hany 2022	0	80	1	80	26.2%	-0.01 [-0.05, 0.02]	2022	+
Wilczyński 2022	0	47	0	33	12.3%	0.00 [-0.05, 0.05]	2022	+
Felsenreich 2022	0	13	0	45	2.9%	0.00 [-0.10, 0.10]	2022	
Rheinwalt 2022	2	55	4	68	5.4%	-0.02 [-0.10, 0.05]	2022	
Total (95% CI)		373		366	100.0%	-0.00 [-0.02, 0.02]		
Total events	4		6					
Heterogeneity: Tau ² =	0.00; Ch	i ^z = 1.1	0, df = 5 (P = 0.9	5); I² = 0%	6		
Test for overall effect:	Z = 0.21	(P = 0.8	33)					Favours [OAGB] Favours [RYGB]

Fig. 3 Forest plot for leak

	OAG	В	RYG	В		Risk Difference		Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
Chiappetta 2019	0	34	0	21	8.5%	0.00 [-0.07, 0.07]	2019	+
Rayman 2021	2	144	3	119	40.0%	-0.01 [-0.05, 0.02]	2021	+
Rheinwalt 2022	0	55	2	68	18.2%	-0.03 [-0.08, 0.02]	2022	-
Wilczyński 2022	1	47	1	33	9.0%	-0.01 [-0.08, 0.06]	2022	+
Hany 2022	2	80	2	80	19.8%	0.00 [-0.05, 0.05]	2022	+
Felsenreich 2022	0	13	0	45	4.5%	0.00 [-0.10, 0.10]	2022	+
Total (95% CI)		373		366	100.0%	-0.01 [-0.03, 0.01]		•
Total events	5		8					
Heterogeneity: Tau ² = Test for overall effect:	0.00; Ch Z = 0.97	i ² = 0.8 (P = 0.3	4, df = 5 (33)	P = 0.9	7); I² = 0%	6		-1 -0.5 0 0.5 1

Fig. 4 Forest plot for bleeding

	OAG	В	RYG	В		Risk Difference		Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
Chiappetta 2019	0	34	1	21	2.3%	-0.05 [-0.16, 0.06]	2019	
Rayman 2021	0	144	0	119	55.3%	0.00 [-0.01, 0.01]	2021	•
Felsenreich 2022	0	13	0	45	2.9%	0.00 [-0.10, 0.10]	2022	
Wilczyński 2022	3	47	4	33	1.7%	-0.06 [-0.19, 0.07]	2022	
Hany 2022	0	80	2	80	14.9%	-0.03 [-0.07, 0.02]	2022	-
Rheinwalt 2022	0	55	0	68	22.8%	0.00 [-0.03, 0.03]	2022	+
Total (95% CI)		373		366	100.0%	0.011.0.02.0.011		
Total (95% CI)		515	-	300	100.0%	-0.01[-0.02, 0.01]		1
l otal events	3		(
Heterogeneity: Tau ² =	0.00; Ch	i² = 5.9	4, df = 5 (P = 0.3	1); I ² = 16	%	ł	
Test for overall effect:	Z = 0.66	(P = 0.5	51)					Favours [OAGB] Favours [RYGB]

Fig. 5 Forest plot for marginal ulcer

	OAG	в	RYG	В		Risk Difference		Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
Chiappetta 2019	5	34	13	21	14.2%	-0.47 [-0.71, -0.23]	2019	
Rayman 2021	28	144	41	119	18.3%	-0.15 [-0.26, -0.04]	2021	
Felsenreich 2022	0	13	27	45	16.4%	-0.60 [-0.77, -0.43]	2022	_ -
Rheinwalt 2022	45	55	63	68	18.0%	-0.11 [-0.23, 0.01]	2022	
Wilczyński 2022	7	47	10	33	16.0%	-0.15 [-0.34, 0.03]	2022	
Hany 2022	33	80	32	80	17.1%	0.01 [-0.14, 0.16]	2022	
Total (95% CI)		373		366	100.0%	-0.24 [-0.41, -0.06]		•
Total events	118		186					
Heterogeneity: Tau ² =	0.04; Ch	i² = 37.0	69, df = 5	(P < 0.	00001); P	²= 87%		
Test for overall effect:	Z = 2.70	(P = 0.0	107)					Favours [OAGB] Favours [RYGB]

Fig. 6 Forest plot for GERD as indication for conversion

	OAG	В	RYG	В		Risk Difference		Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
Chiappetta 2019	1	5	12	13	17.7%	-0.72 [-1.10, -0.34]	2019	← ■───
Rayman 2021	3	28	32	41	21.5%	-0.67 [-0.84, -0.50]	2021	_ - _
Felsenreich 2022	0	0	14	27		Not estimable	2022	
Hany 2022	33	33	32	32	22.6%	0.00 [-0.06, 0.06]	2022	+
Rheinwalt 2022	39	45	56	63	22.0%	-0.02 [-0.15, 0.10]	2022	
Wilczyński 2022	5	7	4	10	16.2%	0.31 [-0.14, 0.77]	2022	
Total (95% CI)		118		186	100.0%	-0.23 [-0.57, 0.11]		
Total events	81		150					
Heterogeneity: Tau² =	0.13; Ch	i ^z = 93.	34, df = 4	(P < 0.	.00001); P	²= 96%		
Test for overall effect:	Z=1.31	(P = 0.1	9)					Favours [OAGB] Favours [RYGB]

Fig. 7 Forest plot for GERD after conversion

	OAG	в	RYG	в		Risk Difference	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Chiappetta 2019	0	29	0	8	16.7%	0.00 [-0.16, 0.16]	
Felsenreich 2022	7	13	0	18	11.7%	0.54 [0.27, 0.81]	
Hany 2022	2	47	1	48	20.2%	0.02 [-0.05, 0.09]	+
Rayman 2021	0	116	0	78	21.2%	0.00 [-0.02, 0.02]	+
Rheinwalt 2022	0	10	0	5	12.4%	0.00 [-0.25, 0.25]	
Wilczyński 2022	7	40	0	23	17.8%	0.17 [0.04, 0.31]	
Total (95% CI)		255		180	100.0%	0.10 [-0.04, 0.24]	•
Total events	16		1				
Heterogeneity: Tau ² =	0.02; Ch	i² = 58.	88, df = 5	(P < 0.	00001); P	²= 92%	
Test for overall effect:	Z=1.40	(P = 0.1	6)				Favours [OAGB] Favours [RYGB]

Fig. 8 Forest plot for de novo GERD after conversion

performed the only available controlled trial demonstrating that after 2 years, both revisional RYGB and OAGB have comparable metabolic outcomes.

Our analysis has demonstrated a low-to-moderate heterogeneity among these studies with a high-quality methodology. Weight loss as TWL%, EWL%, or %EBMIL and rates of early complications (leak, bleeding) were reported in all the papers. Regardless of the used parameter, the mean weight loss after one-anastomosis gastric bypass was higher than after RYGB in all but one of the included articles; thus, the present meta-analysis confirmed the inferiority of RYGB in terms of weight loss. Only Rheinwalt [13] found that the two interventions induced comparable weight loss probably for the long biliopancreatic limb of the RYGB in this study.

Low rates of early complications (leak, bleeding) found in all the collected papers demonstrated the feasibility and safety of revisional surgery after LSG.

Regarding long-term complications, some authors have reported a higher occurrence of marginal ulcer (MU) after revisional surgery [30] especially due to the risk of retained gastric antrum syndrome (RGA) after conversion to gastric bypass [31, 32]. Conversely, in this systematic review, after a follow-up ranging from 12 to 60 months, the rate of MU was 1% both for RYGB and OAGB.

As expected, we found that a higher rate of patients with GERD after LSG was converted to RYGB rather than to OAGB, but remission from GERD was satisfactory and comparable after the two procedures. Even if de novo GERD occurred more frequently after revisional OAGB, new-onset reflux and Barrett's disease were reported after both revisional interventions.

Strength and limitations

Although a meta-analysis [33] was recently published, the present includes two more papers (6 instead of 4) and focuses not only on weight loss but also on the safety (early complications) and on GERD symptoms after revision. The main limitation is that GERD was assessed through different diagnostic methods with a lack of information on severity of GERD, presence and size of eventual hiatal hernia, and degree of esophagitis. Moreover, several revisional procedures were performed together with a concomitant hiatoplasty, which may have influenced the results on reflux. This is particularly interesting for the treatment of patients with severe obesity suffering from GERD and/or hiatal hernia (HH). Even if from 22 to 37% of class three obesity patients have a hiatal hernia (HH) [34], these defects are preoperatively underdiagnosed or not repaired intraoperatively. Conversely, studies with long-term results have demonstrated that SG plus hiatal hernia repair (HHR) induces symptoms relief up to 60% of patients [35]. Considering that GERD itself is a major issue before and after SG, HHR should be considered mandatory for those with severe obesity and GERD undergoing sleeve gastrectomy. Eventually, we must acknowledge that weight loss is mostly influenced by the length of the biliopancreatic limb; therefore, future studies comparing OAGB and RYGB after LSG should take into account the bypassed lengths of small bowel.

Conclusion

Conversion from LSG to RYGB or OAGB is feasible and safe with a low rate of postoperative complications.

Despite weight loss is satisfactory after both procedures, OAGB provides better results. Remission from GERD is higher after RYGB but without statistical significance.

Without knowing the applied bypass length in most of the analyzed studies, OAGB might be a better option for failed LSG, while RYGB still should be preferred in case of severe GERD. Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00423-023-03175-x.

Authors' contributions A.V., R.P., and G.B. did the research and wrote the manuscript. P.C. helped with the research. V.P. reviewed the text.

Funding Open access funding provided by Università degli Studi di Napoli Federico II within the CRUI-CARE Agreement.

Data availability All data are available online since this is a systematic review of published studies.

Declarations

Ethics approval This report does not describe any study with human participants or animals performed by any of the authors.

Competing interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

- Angrisani L, Santonicola A, Iovino P et al (2017) Erratum to: Bariatric surgery and endoluminal procedures: IFSO Worldwide Survey 2014. Obes Surg 27(9):2290–2292. https://doi.org/10. 1007/s11695-017-2773-8
- Felsenreich DM, Langer FB, Kefurt R et al (2016) Weight loss, weight regain, and conversions to Roux-en-Y gastric bypass: 10-year results of laparoscopic sleeve gastrectomy. Surg Obes Relat Dis 12(9):1655–1662
- Genco A, Soricelli E, Casella G et al (2017) Gastroesophageal reflux disease and Barrett's esophagus after laparoscopic sleeve gastrectomy: a possible, underestimated long-term complication. Surg Obes Relat Dis 13(4):568–574
- Felsenreich DM, Kefurt R, Schermann M et al (2017) Reflux, sleeve dilation, and Barrett's esophagus after laparoscopic sleeve gastrectomy: long-term follow-up. Obes Surg 27(12):3092–3101
- Iannelli A, Debs T, Martini F, Benichou B, Ben Amor I, Gugenheim J (2016) Laparoscopic conversion of sleeve gastrectomy to Roux-en-Y gastric bypass: indications and preliminary results. Surg Obes Relat Dis 8:1533–1538
- Parmar CD, Mahawar KK, Boyle M (2017) Conversion of sleeve gastrectomy to Roux-en-Y gastric bypass is effective for gastro-oesophageal reflux disease but not for further weight loss. Obes Surg 27(7):1651–1658. https://doi.org/10.1007/ s11695-017-2542-8
- Kermansaravi M, Shahmiri SS, DavarpanahJazi AH et al (2021) One anastomosis/mini-gastric bypass (OAGB/MGB) as revisional surgery following primary restrictive bariatric procedures: a systematic review and meta-analysis. Obes Surg 1:370–383. https:// doi.org/10.1007/s11695-020-05079-x

- Hamseer L, Moher D, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ Br Med J 349:7647
- 9. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605
- Felsenreich DM, Steinlechner K, Langer FB et al (2022) Outcome of sleeve gastrectomy converted to Roux-en-Y gastric bypass and one-anastomosis gastric bypass. Obes Surg 32(3):643–651. https://doi.org/10.1007/s11695-021-05866-0
- Chiappetta S, Stier C, Scheffel O et al (2019) Mini/one anastomosis gastric bypass versus Roux-en-Y gastric bypass as a second step procedure after sleeve gastrectomy-a retrospective cohort study. Obes Surg 29(3):819–827. https://doi.org/10.1007/ s11695-018-03629-y
- Rayman S, Assaf D, Azran C et al (2021) Sleeve gastrectomy failure-revision to laparoscopic one-anastomosis gastric bypass or Roux-n-Y gastric bypass: a multicenter study. Obes Surg 31(7):2927–2934. https://doi.org/10.1007/s11695-021-05334-9
- Rheinwalt KP, Schipper S, Plamper A et al (2022) Roux-en-Y versus one anastomosis gastric bypass as redo-operations following sleeve gastrectomy: a retrospective study. World J Surg 46(4):855–864. https://doi.org/10.1007/s00268-021-06424-6
- Wilczyński M, Spychalski P, Proczko-Stepaniak M et al (2022) Comparison of the long-term outcomes of RYGB and OAGB as conversion procedures after failed LSG — a case–control study. J Gastrointest Surg 26:2255–2265. https://doi.org/10.1007/s11605-022-05395-w
- Hany M, Zidan A, Elmongui E et al (2022) Revisional Roux-en-Y gastric bypass versus revisional one-anastomosis gastric bypass after failed sleeve gastrectomy: a randomized controlled trial. Obes Surg 11:3491–3503. https://doi.org/10.1007/s11695-022-06266-8
- Auricchio P, Tanay E, Kieninger C et al (2022) Re-do surgery after sleeve gastrectomy: a single center comparison between Roux-en-Y gastric bypass and one anastomosis gastric bypass. Surgeries 3(2):126–133
- Marceau P, Biron S, Bourque RA, Potvin M, Hould FS, Simard S (1993) Biliopancreatic diversion with a new type of gastrectomy. Obes Surg 3(1):29–35. https://doi.org/10.1381/096089293765559728
- Regan JP, Inabnet WB, Gagner M, Pomp A (2003) Early experience with two-stage laparoscopic Roux-en-Y gastric bypass as an alternative in the super-super obese patient. Obes Surg 13(6):861– 864. https://doi.org/10.1381/096089203322618669
- Gumbs AA, Gagner M, Dakin G, Pomp A (2007) Sleeve gastrectomy for morbid obesity. Obes Surg 17(7):962–969. https://doi. org/10.1007/s11695-007-9151-x
- 20 Leyba JL, Aulestia SN, Llopis SN (2011) Laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy for the treatment of morbid obesity. A prospective study of 117 patients. Obes Surg 2:212–6. https://doi.org/10.1007/s11695-010-0279-8
- Hirth DA, Jones EL, Rothchild KB, Mitchell BC, Schoen JA (2015) Laparoscopic sleeve gastrectomy: long-term weight loss outcomes. Surg Obes Relat Dis 11(5):1004–1007. https://doi.org/ 10.1016/j.soard.2015.02.016
- 22. Jain M, Tantia O, Goyal G, Chaudhuri T, Khanna S, Poddar A, Majumdar K, Gupta S (2021) LSG vs MGB-OAGB: 5-year follow-up data and comparative outcome of the two procedures over long term-results of a randomised control trial. Obes Surg 31(3):1223–1232. https://doi.org/10.1007/s11695-020-05119-6
- 23. Peterli R, Wölnerhanssen BK, Peters T et al (2018) Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric

bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial. JAMA 319(3):255–265. https:// doi.org/10.1001/jama.2017.20897

- 24 Musella M, Berardi G, Velotti N et al (2021) Ten-year results of laparoscopic sleeve gastrectomy: retrospective matched comparison with laparoscopic adjustable gastric banding-is there a significant difference in long term? Obes Surg 12:5267–5274. https://doi.org/10.1007/s11695-021-05735-w
- Vitiello A, Berardi G, Velotti N et al (2020) Should sleeve gastrectomy be considered only as a first step in super obese patients?
 5-year results from a single center. Surg Laparosc Endosc Percutan Tech 31(2):203–207. https://doi.org/10.1097/SLE.00000 00000000866
- 26. Milone M, Di Minno MND, Lupoli R et al (2014) Wernicke encephalopathy in subjects undergoing restrictive weight loss surgery: a systematic review of literature data. Eur Eat Disorders Rev 22:223–229. https://doi.org/10.1002/erv.2292
- 27. Oor JE, Roks DJ, Ünlü Ç et al (2016) Laparoscopic sleeve gastrectomy and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Surg 211(1):250–267
- Yeung KTD, Penney N, Ashrafian L, Darzi A, Ashrafian H (2020) Does sleeve gastrectomy expose the distal esophagus to severe reflux? A systematic review and meta-analysis. Ann Surg 271(2):257–265. https://doi.org/10.1097/SLA.00000000003275
- 29. Parmar CD, Bryant C, Luque-de-Leon E et al (2019) One anastomosis gastric bypass in morbidly obese patients with BMI ≥ 50 kg/m2: a systematic review comparing it with Roux-En-Y gastric bypass and sleeve gastrectomy. OBES SURG 29:3039–3046. https://doi.org/10.1007/s11695-019-04034-9
- Clapp B, Hahn J, Dodoo C et al (2019) Evaluation of the rate of marginal ulcer formation after bariatric surgery using the MBSA-QIP database. Surg Endosc 33(6):1890–1897. https://doi.org/10. 1007/s00464-018-6468-6
- 31. Gibril F, Lindeman RJ, Abou-Saif A et al (2001) Case report: retained gastric antrum syndrome. Dig Dis Sci 46:610–617. https://doi.org/10.1023/A:1005667719847
- 32 Abou Hussein B, Al Marzouqi O, Khammas A (2020) Anastomotic gastro-jejunal ulcer perforation following one anastomosis gastric bypass: clinical presentation and options of management case series and review of literature. OBES SURG 30:2423–2428. https://doi.org/10.1007/s11695-020-04423-5
- 33. Dantas ACB, Branco LT, Tustumi F, de Oliveira DRCF, Pajecki D, Santo MA (2022) One-anastomosis gastric bypass versus Rouxen-Y gastric bypass as revisional surgery after sleeve gastrectomy: a systematic review and meta-analysis. Obes Surg 32(12):4082– 4088. https://doi.org/10.1007/s11695-022-06326-z
- Sakata S, Grove PM, Stevenson AR (2016) Effect of 3-dimensional vision on surgeons using the da vinci robot for laparoscopy: more than meets the eye. JAMA Surg 151:793–794. https://doi. org/10.1001/jamasurg.2016.0412
- 35. Angrisani L, Santonicola A, Borrelli V et al (2020) Sleeve gastrectomy with concomitant hiatal hernia repair in obese patients: long-term results on gastroesophageal reflux disease. Surg Obes Relat Dis 16(9):1171–1177. https://doi.org/10.1016/j.soard.2020. 04.049

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.